Related Experiment Video
Updated: Aug 9, 2026
Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
Published on: September 14, 2014
Epitope mapping of the major Epstein-Barr virus outer envelope glycoprotein gp350/220
Abstract:
To understand the complete immunochemical structure of the Epstein-Barr virus (EBV) major membrane glycoprotein gp350/220, monoclonal antibodies (MAbs) reacting with this important viral antigen were isolated. Through competitive inhibition binding studies, it was determined that a group of 18 IgG MAbs recognized seven distinct epitopes on the gp350/220 molecule. Eight of these MAbs fell into a single epitope group with four of those MAbs, as well as a single MAb from another epitope group, being capable of neutralizing EBV strain B95-8 transformation of umbilical cord lymphocytes.
Insights
Researchers identified seven distinct epitopes on Epstein-Barr virus (EBV) glycoprotein gp350/220 using monoclonal antibodies. Some antibodies neutralized EBV, offering insights into viral structure and potential therapeutic targets.
Area of Science:
- Virology
- Immunology
- Structural Biology
Background:
- The Epstein-Barr virus (EBV) major membrane glycoprotein gp350/220 is crucial for viral entry and infectivity.
- Understanding its immunochemical structure is key to developing targeted antiviral strategies.
Purpose of the Study:
- To elucidate the complete immunochemical structure of the EBV gp350/220 glycoprotein.
- To identify distinct epitopes recognized by monoclonal antibodies (MAbs) on the gp350/220 molecule.
Main Methods:
- Isolation of monoclonal antibodies (MAbs) against EBV gp350/220.
- Competitive inhibition binding assays to determine epitope specificity.
Main Results:
- 18 IgG MAbs recognized seven distinct epitopes on the EBV gp350/220 glycoprotein.
- A subset of these MAbs demonstrated neutralizing activity against EBV strain B95-8, inhibiting lymphocyte transformation.
Conclusions:
- The study maps key epitopes on EBV gp350/220, revealing structural complexity.
- Identified neutralizing MAbs provide a basis for potential EBV-targeted therapies and diagnostics.
